KONSTANTIN TETELMAN: Open Payments
NPI 1447836457 · FORT WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$416 in 9 payments from 6 companies in 2025. Trend: 2023 $234 · 2024 $664 · 2025 $416
Food & beverage: $416
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 2 | $138 |
| E.R. Squibb & Sons, L.L.C. | 1 | $121 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
Products named: ARISTADA, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, INVEGA SUSTENNA, SPRAVATO, ERZOFRI EXTENDED-RELEASE.
Industry payments across PA — which companies pay providers there.
